Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Income from Continuing Operations (2024 - 2026)

Kura Oncology has reported Income from Continuing Operations over the past 3 years, most recently at 73333000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 27.69% to 73333000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 16201000.0 through Mar 2026, up 90.99% year-over-year, with the annual reading at 297000.0 for FY2025, 99.83% up from the prior year.
  • Income from Continuing Operations was 73333000.0 for Q1 2026 at Kura Oncology, down from 197370000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 197370000.0 in Q4 2025 and troughed at 74116000.0 in Q3 2025.
  • The 3-year median for Income from Continuing Operations is 54404000.0 (2024), against an average of 27288333.33.
  • The largest YoY upside for Income from Continuing Operations was 1247.57% in 2025 against a maximum downside of 36.23% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 17199000.0 in 2024, then soared by 1247.57% to 197370000.0 in 2025, then crashed by 137.16% to 73333000.0 in 2026.
  • Per Business Quant, the three most recent readings for KURA's Income from Continuing Operations are 73333000.0 (Q1 2026), 197370000.0 (Q4 2025), and 74116000.0 (Q3 2025).